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Abstract. In the conditions of introduction of the proper practice of production of medicinal facilities 
on pharmaceutical enterprises in Ukraine, it is necessary to develop effective measures of projects 
management for creation of favourable conditions for modernisation of pharmaceutical production, 
innovative management and management of development projects. The optimization of 
pharmaceutical production of injection preparations, modernisation of the pharmaceutical industries, is 
being implemented in accordance with the standards of GMP. 
Risks-control of  pharmaceutical production of hi-tech parenteral preparations on a new level is 
carried out at the following stages: preparation of raw material, preparation of facilities and 
equipment; the process of preparation of solution (the stage of preparation of solution, the stage of 
sterile filtration; filling, small bottles, ampoules and cartridges; washing small bottles, ampoules and 
cartridges, preparation of materials for corking, sterilization of components; soldering of ampoules, 
rolling of small bottles and cartridges; sterilization and checking for impermeability).  
Decreasing the risk focuses on the processes of reduction and prevention of risk and its causes, 
when the risk exceeds the indicated acceptable level. Decreasing the risk can include the 
measures of declining of authenticity of harm. Conclusions regarding the measures related to 
decreasing the risk can bring to the exposure of potential threats and new hidden risks. 
Keywords: pharmaceutical production; injection preparations; innovative management; 
management of development projects; good manufacturing practice. 
Гой А.М.1,  
Воскобойникова Г.Л.2, 
Гапон Н.В.3,  
Кузнец Д.О.4 
ИССЛЕДОВАНИЯ И ОБОСНОВАНИЕ ДИЗАЙНА 
ФАРМАЦЕВТИЧЕСКОЙ РАЗРАБОТКИ ПРОМЫШЛЕННОГО 
ВНЕДРЕНИЯ В ПРОИЗВОДСТВО ПАРЕНТЕРАЛЬНЫХ ПРЕПАРАТОВ 
НА ОСНОВЕ РЕКОМБИНАНТНЫХ БЕЛКОВ 
1) руководитель Департамента исследований и разработки ПАТ «Фармак», г. Киев, Украина.
2) старший специалист Центральной лаборатории фармацевтической разработки Департамента исследований и
разработки ПАТ «Фармак», професор кафедры управления качеством, стандартизации и безопасности применения 
лекарственных средств, кандидат фармацевтических, доктор педагогических наук, профессор, Киевский 
Международный Университет, E-mail: G_Vosk@ukr.net 
3) Инженер-технолог, Центральная лаборатория фармацевтической разработки ПАТ «Фармак»
4) Инженер по подготовке досье, Отдел подготовки и управления досье ПАТ «Фармак»
Аннотация. В условиях введения надлежащей практики производства лекарственных 
средств на фармацевтических предприятиях в Украине в фармацевтической системе 
качества необходимо эффективное управление проектами для создания благоприятных 
сроков модернизации фармацевтического производства, инновационного управления и 
управления проектами развития. Оптимизация фармацевтического производства 
инъекционных препаратов и модернизация в сфере промышленной фармации 
осуществляется в соответствии со стандартами GMP. 
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Риск-контроль фармацевтического производства высокотехнологичных парентеральных 
препаратов на новом уровне осуществляется на стадиях: приготовления сырьевого 
материала, приготовление помещений и оборудования; процесс приготовления раствора 
(стадия приготовления раствора, стадия стерильной фильтрации; стерильный розлив во 
флаконы, ампулы и картриджи; мойка флаконов, ампул и картриджей, приготовления 
материалов для закупорки, стерилизация компонентов; запайка ампул, обкатка 
флаконов и картриджей; стерилизация и проверка герметичности). 
Снижение риска сосредоточивается на процессах снижения и предупреждая 
возникновения риска, источников происхождении, когда риск превышает номинальный 
приемлемый уровень. Снижение риска может включать меры отклонения подлинности 
вреда. Выводы по существу относительного снижения риска могут приводить к 
выявлению потенциальных угроз и новых скрытых рисков. 
Ключевые слова: фармацевтическое производство, парентеральные препараты, 
инновационное управление, управление проектами развития, надлежащая 
производственная практика. 
 
Introduction. In the conditions of introduction 
of the proper practice of production of medicinal 
products at pharmaceutical enterprises in Ukraine, it 
is necessary to develop effective measures of projects 
management for creation of favourable conditions for 
modernisation of pharmaceutical production, 
innovative management and management of 
development projects.  
Optimization of pharmaceutical production of 
injection preparations and modernisation of injection 
areas is being carried out in accordance with the 
standards of GMP. Project management  includes 
aseptic and sterile production, beginning from 
washing, sterilization of materials, by next aseptic 
production, completing eventual sterilization of 
pharmaceutical product, or sterile filtration, overflow 
and packing in aseptic terms, also plugs possibility of 
aseptic production of parenteral medical forms in 
vials and cartridges. 
Over the past 10 years, the development of 
biotechnological methods allowed to create and 
implement new analogues of human insulin in curative 
practice, that possess additional therapeutic advantages 
at maintenance of valuable hypoglycemia activity. The 
examples of such introductions are analogues of insulin 
of urgent (LISPRO and ASPART) and prolonged 
(GLARGIN, DETEMIR) action. 
The process of obtaining of insulin and its 
analogues in bacterial expression systems 
conventionally can be divided into the next stages: 
fermentation (growing of stamm-producent  in a 
fermenter); separation of biomasses and 
disintegration of cellular suspension  with the 
selection of bodies of including; selection and 
cleaning of recombinant proteins; enzymolysis of 
recombinant proteins; chromatography cleaning of 
insulin or its analogues; obtaining of crystalline 
insulin or its analogues.    
Pharmaceutical preparations that are not accessible 
for thermal sterilization (sterilized by other methods: 
chemical, filtration, radiation), in particular bioorganic 
preparations, recombinant proteins are prepared in 
aseptic condition with further use of innovative 
methodologies: chromatography division, application of 
the special chromatography columns. The newest 
achievements of improvement of technological 
processes of receipt of parenteral preparations are 
considered in scientific reviews [1; 2]. 
Analysing the results of Aseptic Live Show 
industrial production of parenteral medicinal products 
of pharmaceutical industry enterprises specialized in the 
production of automatic and aseptic packing machines, 
one should note that the situation has radically changed. 
It is predefined by contradictions between principles of 
the old and new pharmaceutical engineering. The new 
pharmaceutical engineering needs some new 
technological and non-standard decisions related to 
reduction of time of disinfection and drying of 
capacities for parenteral medicinal products.  
Sterility means the absence of all viable 
microorganisms including viruses. At present, a 
sterility assurance level (SAL) of 10
–6
 is generally 
accepted for pharmacopoeial sterilization procedures, 
i.e., the probability of not more than one viable 
microorganism in an amount of one million sterilised 
items of the final product. By extrapolating the 
reduction rates following extreme artificial initial 
contamination, the theoretical overall performance of 
the procedure of at least 12 lg increments (overkill 
conditions) is demanded to verify an SAL of 10
–6
. By 
comparison, other recommendations for thermal 
sterilization procedures demand only evidence that 
the difference between the initial contamination and 
the number of test organisms at the end of the process 
amount to more than six orders of magnitude. 
However, the practical proof of the required level of 
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sterility assurance of 10
–6
 is not possible. Moreover, 
the attainability of this condition is fundamentally 
dubious, at least in non-thermal procedures. Thus, the 
question is discussed whether the undifferentiated 
adherence to the concept of sterility assurance on the 
basis of a single SAL of 10
–6
 corresponds with the 
safety requirements in terms of patient or user safety, 
costs and energy efficiency. Therefore, in terms of 
practical considerations, a concept of tiered SALs is 
recommended, analogous to the comparable and 
well-established categorization into “High-level 
disinfection”, “Intermediate-level disinfection” and 
“Low-level disinfection”. The determination of such 
tiered SALs is geared both to the intended application 
of the sterilized goods, as well as to the 
characteristics of the products and the corresponding 
treatment options [ 3; 4; 5; 6]. 
In the case of aseptic preparation, filling and 
production procedures, a mean contamination 
probability of 10
–3
 is assumed. In automated processes, 
lower contamination rates can be realized. In the case of 
the production of re-usable medical devices, a reduction 
of at least 2 lg increments can be achieved through prior 
cleaning in validated cleaning and disinfecting devices. 
By chemical disinfection, a further reduction of ≥5 lg 
increments is achieved. In the case of sterilized surgical 
instruments, an additional concern is that they lie 
opened in the contaminated air for the duration of the 
operation, at least in conventionally ventilated operating 
theaters. Finally, the amount of pathogens necessary to 
cause an infection must be considered. By logical 
consideration of all aspects, it seems possible to 
partially reduce sterility assurance levels without any 
loss of safety. Proceeding from this, we would like to 
make the following suggestions for tiered SAL values, 
adjusted according to the respective sterilization task: 
SAL 10
–6
 for heat-resistant pharmaceutical preparations 
(parenterals), suggested term: “Pharmaceutical 
sterilization”; SAL 10–4 for heat-resistant medical 
devices, suggested term: “High-level sterilization”; 
SAL 10
–3
 for heat-sensitive re-usable medical devices, 
under the precondition of a validated cleaning efficacy 
of >4 lg increments, suggested term: “Low-level 
sterilization” [6]. 
Methods. Planning, design of technological 
process, imitation design taking into account 
provocative terms, analysis of the systems and 
estimation of risks of pharmaceutical production. 
Results and discussions.  
The features of processes and operations of 
pharmaceutical production of hi-tech parenteral 
preparations include planning, architectural and air-
technical decisions for the clean facilities of 
productive area, that provide the class of cleanness 
(B, С, D), elements of asepsis. 
Imitation of the process of production of insulins 
in cartridges with the use of growth media of TSB on 
an injection area  №1 on one model series of 
production of insulins, on the example of preparation  
of Farmasuline Н solution for injections 100 МЕ/ml 
for 3 mls in a cartridge, takes into account the 
features of production of this pharmaceutical product. 
Validation test of aseptic process of filling of 
cartridges is based on realization of planning 
researches – the simulation of aseptic process with 
the use of the growth media (periodicity of 6 + 1 
months), pre-arranged by protocol of 01-04-ААА- of 
MFTP – 2.0 on an injection area №1. The aim of 
validation tests is in receiving of convincing results, 
that in high degree will confirm the authenticity, that 
process of preparing, filtration, filling, capping of 
cartridges is provided by the necessary level of 
sterility of product in accordance with the 
requirements of ST-N Ministry of health care of 
Ukraine 42-4.0:2011 Medicinal products.GMP.  
The algorithm of validation tests of the process 
of aseptic filling of cartridges includes testing of such 
stages: preparation of shop floors (01-04 – MFTP – 
1); preparation of equipment (01-04 – MFTP – 2); 
preparation of raw material and materials (01-04 – 
MFTP – 3); preparation of solution (01-04 – MFTP – 
4); filtration of coregent (01-04 – MFTP – 4.1); 
filtration of solution (01-04 – MFTP – 5); filling and 
capping of cartridges (01-04 – MFTP – 6);  filling 
and rolling of cartridges, implementation of aseptic 
manipulations (01-04 – MFTP – 7);  checking of 
cartridges  for impermeability (01-04 – MFTP – 8);  
visual inspection and sorting of gap-filling cartridges 
(01-04 – MFTP – 9); the microbiological monitoring 
during a technological process (01-04 – MFTP – 10); 
incubation of gap-filling standards (01-04 – MFTP – 
11); inspection of cartridges (01-04 – MFTP – 12); 
verification of heighting properties of nourishing 
media (01-04 – MFTP – 13). 
Quality and risk management includes the 
systematic processes, intended for co-ordination, 
facilitation and perfection of scientific decisions in 
relation to risks. For realization of quality and risk 
management of the pharmaceutical production of hi-
tech parenteral preparations on the new area 
constructed in accordance with introduction of the 
authorial project the "Universal integrated model of 
organization of pharmaceutical production of 
parenteral preparations"© there should be conducted 
the following: determination of the problem related to 
the risk, relevant suppositions identifying risk 
possibility;  collection of information  on a potential 
danger; setting of leader and determination of 
necessary resources. Draft chart of control of the pre-
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arranged results in accordance with made decision for 
the process of risk management is drafted below.  
The risk-management of aseptic production 
comes true in accordance with the ISO standard [7].  
The risk estimation includes authentication of 
dangers; analysis and determination of risk size, 
related to the dangers. The estimation of risks of 
quality is begun with determination of essence of 
problem of quality [7; 8]. 
Discipline in realization effective risk 
management of aseptic production is regulator 
documents WHO, FDA, EMEA [8; 9; 10]. 
Normative documentation for parenteral 
preparations on the area of production: apparatus 
chart (PID); analytical and normative documentation 
(AND); specification of raw material and critical 
auxiliary materials for preparations on the area of 
production "Production of liquid medicinal facilities 
in vials and cartridges" (S); Technical Conception of 
Project (URS). 
The formalized estimation of risks is conducted 
in accordance with the following chart (picture 1) : 
 
Picture 1. Chart of formalized estimation of risks. 
 
Risk control of pharmaceutical production of hi-
tech parenteral preparations on a new area is 
performed on the following stages: preparation of 
raw material, preparation of areas and equipment; 
process of preparation of solution (stage of 
preparation of solution, stage of sterile filtration; 
filling in vials, ampoules and cartridges; washing of 
vials, ampoules and cartridges, preparation of 
materials for stoppering, sterilization of components; 
ampoule sealing, capping of vials and cartridges; 
sterilization and checking for impermeability).  
Coming from mark reasons and degree of 
criticism of risks, methods of their minimization will 
be invented, so as methods of estimation of efficiency 
of the chosen measures. Therefore, exactly the 
estimation of risks allows working out the detailed 
plan of preparation to the test by nourishing media as 
a finishing chord of start of aseptic production. 
Conclusion.  
A perspective direction of researches of further 
development of the pharmaceutical industry and 
biotechnologies includes the development and industrial 
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introduction of preparations of the prolonged action 
insulin based on the universal integrated model of cycle 
of pharmaceutical production of parenteral preparations 
according to ІСН.  
Control of risk includes making decision with 
the aim of reducing to the acceptable level or 
acceptance of risk. Efforts given for risk control 
should be proportional to the risk value. Risk control 
determines the following: a risk which level is 
acceptable; what measures should be accepted for the 
declining of risk; what corresponding balance of risks 
and resources should be; whether there are new risks 
by the result of the controlled and identified risks of 
technological process. 
Risk reduction focuses on the processes of 
reducing and preventing the emergence of risk, 
sources of origin, when the risk exceeds the rated 
acceptable level. Risk reduction may include 
measures of deviation of authenticity harm. The 
findings on the merits of the relative risk reduction 
could lead to the identification of potential threats 
and new hidden risks. Introduction of measures in 
relation to the risk reduction can lead to the exposure 
of potential threats and new hidden risks. Thus can be 
necessary to repeat estimation of risks for 
authentication of any changes of risk after application 
of risk reduction measures. 
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